Your browser doesn't support javascript.
loading
Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring: a Denosumab Experience.
Aydin, Ozgur; Aykas, Fatma.
Afiliação
  • Aydin O; Antalya Research and Education Hospital, Central Laboratory, Antalya, Turkey.
  • Aykas F; Antalya Research and Education Hospital, Hematology Clinic, Antalya, Turkey.
Lab Med ; 54(3): e95-e97, 2023 May 02.
Article em En | MEDLINE | ID: mdl-36221992
A 73-year-old woman was diagnosed with a lambda light chain myeloma. A follow-up immunofixation electrophoresis showed a monoclonal immunoglobulin (Ig)G kappa in addition to the regular lambda band. A monoclonal antibody therapy interference was suspected but her VRD (bortezomib, lenalidomide, dexamethasone) regimen did not include such a medication. Later it was learned that she was prescribed denosumab, a monoclonal human antibody agent to treat bone lesions. The IgG kappa band disappeared 7 months after the first and 4 months after the last dose of denosumab, confirming a case of interference. This case once again emphasizes the importance of delta check and close communication between clinicians to avoid a false result in electrophoresis. It also describes the migration pattern of denosumab. As therapeutic antibodies gain approval and enter into common clinical practice, drug interference will complicate electrophoresis testing in diagnosis and patient follow-up.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / Gamopatia Monoclonal de Significância Indeterminada / Mieloma Múltiplo Limite: Aged / Female / Humans Idioma: En Revista: Lab Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Turquia País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraproteinemias / Gamopatia Monoclonal de Significância Indeterminada / Mieloma Múltiplo Limite: Aged / Female / Humans Idioma: En Revista: Lab Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Turquia País de publicação: Reino Unido